(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Savara's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast SVRA's revenue for 2026 to be $753,517,359, with the lowest SVRA revenue forecast at $0, and the highest SVRA revenue forecast at $1,291,041,436. On average, 9 Wall Street analysts forecast SVRA's revenue for 2027 to be $14,919,110,888, with the lowest SVRA revenue forecast at $9,559,444,585, and the highest SVRA revenue forecast at $20,818,555,467.
In 2028, SVRA is forecast to generate $34,802,788,414 in revenue, with the lowest revenue forecast at $28,597,592,435 and the highest revenue forecast at $44,071,646,213.